Gillespie MS, Ward CM, Davies CC. DNA Repair and Therapeutic Strategies in Cancer Stem Cells. Cancers. 2023;15:1897.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu M-F, et al. Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy. Jnci J Natl Cancer Inst. 2008;100:672–9.

Article  CAS  PubMed  Google Scholar 

Rezayatmand H, Razmkhah M, Razeghian-Jahromi I. Drug resistance in cancer therapy: the Pandora’s Box of cancer stem cells. Stem Cell Res Ther. 2022;13:181.

Article  PubMed  PubMed Central  Google Scholar 

Bellio C, DiGloria C, Foster R, James K, Konstantinopoulos PA, Growdon WB, et al. PARP inhibition induces enrichment of DNA repair proficient CD133 and CD117 positive ovarian cancer stem cells. Mol Cancer Res. 2018;17:molcanres.0594.2018.

Google Scholar 

Lim YC, Roberts TL, Day BW, Harding A, Kozlov S, Kijas AW, et al. A role for homologous recombination and abnormal cell-cycle progression in radioresistance of glioma-initiating cells. Mol Cancer Therapeutics. 2012;11:1863–72.

Article  CAS  Google Scholar 

Abad E, Civit L, Potesil D, Zdrahal Z, Lyakhovich A. Enhanced DNA damage response through RAD50 in triple negative breast cancer resistant and cancer stem‐like cells contributes to chemoresistance. FEBS J. 2021;288:2184–202.

Article  CAS  PubMed  Google Scholar 

Azzoni V, Wicinski J, Macario M, Castagné M, Finetti P, Ambrosova K, et al. BMI1 nuclear location is critical for RAD51-dependent response to replication stress and drives chemoresistance in breast cancer stem cells. Cell Death Dis. 2022;13:96.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen H, Lorton B, Gupta V, Shechter D. A TGFβ-PRMT5-MEP50 axis regulates cancer cell invasion through histone H3 and H4 arginine methylation coupled transcriptional activation and repression. Oncogene. 2016;36:373–86.

Article  PubMed  PubMed Central  Google Scholar 

Powers MA, Fay MM, Factor RE, Welm AL, Ullman KS. Protein arginine methyltransferase 5 accelerates tumor growth by arginine methylation of the tumor suppressor programmed cell death 4. Cancer Res. 2011;71:5579–87.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang F, Wang J, Ren H-Y, Jin J, Wang A-L, Sun L-L, et al. Proliferative role of TRAF4 in breast cancer by upregulating PRMT5 nuclear expression. Tumour Biol J Int Soc Oncodev Biol Med. 2015;36:5901–11.

Article  CAS  Google Scholar 

Xu Y, Li X, Zhang S, Tang M, Yu R, Liao X, et al. CircMMP2(6,7) Cooperates with β-Catenin and PRMT5 to Disrupt Bone Homeostasis and Promote Breast Cancer Bone Metastasis. Cancer Res. 2023;84:328–43.

Article  Google Scholar 

Zhang J, Fan X, Zhou Y, Chen L, Rao H. The PRMT5-LSD1 axis confers Slug dual transcriptional activities and promotes breast cancer progression. J Exp Clin Cancer Res. 2022;41:191.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu Y, Wang Z, Zhang J, Ling R. Elevated expression of protein arginine methyltransferase 5 predicts the poor prognosis of breast cancer. Tumour Biol J Int Soc Oncodev Biol Med. 2017;39:1010428317695917.

Article  Google Scholar 

Liang Z, Liu L, Wen C, Jiang H, Ye T, Ma S, et al. Clinicopathological and Prognostic Significance of PRMT5 in Cancers: A System Review and Meta-Analysis. Cancer Control. 2021;28:10732748211050584.

Article  Google Scholar 

Chiang K, Zielinska AE, Shaaban AM, Sanchez-Bailon MP, Jarrold J, Clarke TL, et al. PRMT5 Is a Critical Regulator of Breast Cancer Stem Cell Function via Histone Methylation and FOXP1 Expression. Cell Rep. 2017;21:3498–513.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brehmer D, Beke L, Wu T, Millar HJ, Moy C, Sun W, et al. Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small Molecule Inhibitor of PRMT5 with Potent Anti-Tumor Activity. Mol Cancer Ther. 2022;20:2317–8.

Bonday ZQ, Cortez GS, Grogan MJ, Antonysamy S, Weichert K, Bocchinfuso WP, et al. LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity. ACS Med Chem Lett. 2018;9:612–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fong JY, Pignata L, Goy P-A, Kawabata KC, Lee SC-W, Koh CM, et al. Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation. Cancer Cell. 2019;36:194–209.e9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu Q, Schapira M, Arrowsmith CH, Barsyte-Lovejoy D. Protein arginine methylation: from enigmatic functions to therapeutic targeting. Nat Rev Drug Discov. 2021;20:509–30.

Jarrold J, Davies CC. PRMTs and Arginine Methylation: Cancer’s Best-Kept Secret? Trends Mol Med. 2019;25:993–1009.

Article  CAS  PubMed  Google Scholar 

Owens JL, Beketova E, Liu S, Tinsley SL, Asberry AM, Deng X, et al. PRMT5 Cooperates with pICln to Function as a Master Epigenetic Activator of DNA Double-Strand Break Repair Genes. Iscience. 2020;23:100750.

Article  CAS  PubMed  Google Scholar 

Guo Z, Zheng L, Xu H, Dai H, Zhou M, Pascua MR, et al. Methylation of FEN1 suppresses nearby phosphorylation and facilitates PCNA binding. Nat Chem Biol. 2010;6:766–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

He W, Ma X, Yang X, Zhao Y, Qiu J, Hang H. A role for the arginine methylation of Rad9 in checkpoint control and cellular sensitivity to DNA damage. Nucleic acids Res. 2011;39:4719–27.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Clarke TL, Sanchez-Bailon MP, Chiang K, Reynolds JJ, Herrero-Ruiz J, Bandeiras TM, et al. PRMT5-Dependent Methylation of the TIP60 Coactivator RUVBL1 Is a Key Regulator of Homologous Recombination. Mol Cell. 2017. https://doi.org/10.1016/j.molcel.2017.01.019.

Rehman I, Basu SM, Das SK, Bhattacharjee S, Ghosh A, Pommier Y, et al. PRMT5-mediated arginine methylation of TDP1 for the repair of topoisomerase I covalent complexes. Nucleic Acids Res. 2018;46:5601–17.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Carter J, Hulse M, Sivakumar M, Burtell J, Thodima V, Wang M, et al. PRMT5 Inhibitors Regulate DNA Damage Repair Pathways in Cancer Cells and Improve Response to PARP Inhibition and Chemotherapies. Cancer Res Commun. 2023;3:2233–43.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Du C, Li SW, Singh SX, Roso K, Sun MA, Pirozzi CJ, et al. Epigenetic regulation of Fanconi anemia genes implicates PRMT5 blockage as a strategy for tumor chemosensitization. Mol Cancer Res. 2021;19:molcanres.MCR-21-0093-A.2021.

Google Scholar 

Chang C-H, Zhang M, Rajapakshe K, Coarfa C, Edwards D, Huang S, et al. Mammary Stem Cells and Tumor-Initiating Cells Are More Resistant to Apoptosis and Exhibit Increased DNA Repair Activity in Response to DNA Damage. Stem Cell Rep. 2015;5:378–91.

Article  CAS  Google Scholar 

Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 2005;65:5506–11.

Article  CAS  PubMed  Google Scholar 

Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003;100:3983–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Harrison H, Farnie G, Howell SJ, Rock RE, Stylianou S, Brennan KR, et al. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res. 2010;70:709–18.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou Z, Feng Z, Hu D, Yang P, Gur M, Bahar I, et al. A novel small-molecule antagonizes PRMT5-mediated KLF4 methylation for targeted therapy. Ebiomedicine. 2019;44:98–111.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chan-Penebre E, Kuplast KG, Majer CR, Boriack-Sjodin PA, Wigle TJ, Johnston LD, et al. A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models. Nat Chem Biol. 2015;11:432–7.

Duncan KW, Rioux N, Boriack-Sjodin PA, Munchhof MJ, Reiter LA, Majer CR, et al. Structure and Property Guided Design in the Identification of PRMT5 Tool Compound EPZ015666. ACS Med Chem Lett. 2016;7:162–6.

Article